Surface modification of poly(lactide-co-glycolide) nanoparticles by d-α-tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 392, Issue 1, 2011, Pages 335-342

  Jalali, Newsha ^a   Moztarzadeh, Fathollah ^a   Mozafari, Masoud ^a   Asgari, Shadnaz ^b   Motevalian, Manijeh ^c   Alhosseini, Sanaz Naghavi ^a  

^a AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brain; Carrier; Drug delivery; PLGA nanoparticles; Surface modification; Vitamin E TPGS

Indexed keywords

BRAIN; CELL CULTURE; DRUG DELIVERY; EMULSIFICATION; GLYCOLS; MORPHOLOGY; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYETHYLENES; SURFACE TREATMENT; THERMOPLASTICS;

AVERAGE PARTICLE SIZE; CARRIER; CELL VIABILITY; CELLULAR VIABILITY; DISTRIBUTION OF PARTICLES; EMULSIFYING EFFECT; IN-VITRO; NATURAL SOURCES; NEUROLOGICAL SYMPTOMS; PC12 CELLS; PLGA NANOPARTICLES; POLY-LACTIDE-CO-GLYCOLIDE; POTENTIAL HEALTH; STIRRING TIME; SYNERGISTIC ACTIVITY; THERAPEUTIC EFFECTS; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATES; VITAMIN E TPGS; VITAMIN-E;

SURFACE MORPHOLOGY;

NANOPARTICLE; POLYGLACTIN; TOCOFERSOLAN;

ARTICLE; BIOCOMPATIBILITY; CELL STRAIN; CELL VIABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HYDROPHOBICITY; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY;

EID: 82855161260     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2011.10.012     Document Type: Article

References (56)

1. Abbott N.J., Romero I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 1996, 2:106-113.
2. Abbott J. Physiology of the blood-brain barrier and its consequences for drug transport to the brain. Int. Congr. Ser. 2005, 277:3-18.
3. Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today 2007, 129(1-2):54-61.
4. Roney C., Kulkarni P., Arora V., Antich P., Bonte F., Wu A., et al. Targeted Nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control. Release 2005, 108(2-3):193-214.
5. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47(1):65-81.
6. Zhao H.W., Zhan Y.W., Chang S.S., Chun Y.W., Tong Y.J., Si L.W. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010, 31:908-915.
7. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxolò). J. Control. Release 2002, 80:129-144.
8. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
9. Duvvuri S., Janoria K.G., Mitra A.K. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J. Control. Release 2005, 108:282-293.
10. Park K. Controlled Drug Delivery: Challenges and Strategies 1997, American Chemical Society, Washington, DC.
11. Lu Z., Bei J.Z., Wang S.G. A method for the preparation of polymeric nanocapsules without stabilizer. J. Control. Release 1999, 61:107-112.
12. Eastman Chemical Company, Vitamin E TPGS NF, Properties and applications, Publication EFC-226A, Kingsport, TN, October 1998.
13. Traber M.G., Kayden H.J., Green J.B., Green M.H. Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. Am. J. Clin. Nutr. 1986, 44:914-923.
14. Sokol R.J., Johnson K.E., Karrer F.M., Narkewicz M.R., Kam I., et al. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991, 338:212-215.
15. Sokol R.J., Johnson K.E., Karrer F.M., Narkewicz M.R., Kam I., et al. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991, 338:697.
16. Argao E.A., Heubi J.E., Hollis B.W., Tsang R.C. d-alpha-Tocopheryl polyethylene glycol-1000 succinate enhances the absorption of vitamin D in chronic cholestatic liver disease of infancy and childhood. Pediatr. Res. 1992, 31:146-150.
17. Bridgers A., Vickers A., Yu L., Silver I., Coffin M. Vitamin E-TPGS enhances the absorption of a model HIV protease inhibitor by inhibiting an apically polarized efflux system. Pharm. Sci. Suppl. 1998, 1(1):S76.
18. Chang T., Benet L.Z., Hebert M.F. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 1996, 59:297-303.
19. Ismailos G., Reppas C., Macheras P. Enhancement of cyclosporin A solubility by d-alpha-tocopherylpolyethylene-glycol-1000 succinate (TPGS). Eur. J. Pharm. Sci. 1994, 1:269-271.
20. Binder H.J., Solitare G.B., Spiro H.M. Neuromuscular disease in patients with steatorrhoea. Gut 1967, 8(6):605-611.
21. Roghani M., Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. 2001, 892:211-217.
22. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989, 52:381-389.
23. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology 1990, 40:32-37.
24. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993, 16:439-444.
25. Russel J., Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 1998, 56:359-384.
26. Fariss M.W., Zhang J.G. Vitamin E therapy in Parkinson's disease. Toxicology 2003, 189:129-146.
27. Nikam S., Nikam P., Ahaley S.K., Sontakke A.V. Oxidative stress in Parkinson's disease. Indian J. Clin. Biochem. 2009, 24(1):98-101.
28. Bhumik D., Medin J., Colmenms G. Mutational analysis of active site residue of human adenosine deaminase. J. Biol. Chem. 1993, 8268:5461-5470.
29. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and anti oxidant therapy in Parkinson's disease. Prog. Neurobiol. 1996, 48:1-19.
30. Stoof J.C., Vermeulen R.J., Van royen E.A., Drukarch B., Voorn P., Wolters E.C., Groenewegen H.J. Dopaminergic systems and Parkinson's disease: some latest developments in pathogenetic, diagnostics and pharmacotherapeutic investigations. Neurosci. Res. Commun. 1996, 18:133-141.
31. Amano S., Ohashi M., Kirihara M., Yang X.H., Hazama F. A tocopherol protects against radical-induced injury in cultured neurons. Neurosci. Lett. 1994, 170:55-58.
32. De Rijk M.C., Breteler M.M.B., Den Breeijen J.H., Launer L.J., Grobbee D.E., Van der Meche F.G.A., Hofman A. Dietary anti-oxidants and Parkinson's disease. Arch. Neurol. 1997, 54:762-766.
33. Zhang Z., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
34. Feng S.S, Huang G.F. Effects of emulsifiers on the controlled release of paclitaxel (Taxol (R)) from nanospheres of biodegradable polymers. J. Control. Release 2001, 71:53-69.
35. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol (R)). J. Control. Release 2002, 80:129-144.
36. Mu L., Feng S.S. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm. Res. 2003, 20:1864-1872.
37. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol (R)): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 2003, 86:33-48.
38. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly(d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 2002, 82(1):105-114.
39. De Maria P., Fontana A., Siani G., D'Aurizio E., Cerichelli G., Chiarini M., Angelini G., Gasbarri C. Synthesis and aggregation behaviour of a new sultaine surfactant. Colloids Surf. Biointerfaces 2011, 87(1):73-78.
40. Song K.C., Lee H.S., Choung I.Y., Cho K.I., Ahn Y., Choi E.J. The effect of type of organic phase solvents on the particle size of poly(d,l-lactide-co-glycolide) nanoparticles. Colloids and Surfaces A: Physicochem. Eng. Aspects 2006, 276:162-167.
41. Song K.C., Lee H.S., Choung I.Y., Cho K.I., Ahn Y., Choi E.J. The effect of type of organic phase solvents on the particle size of poly(d,l-lactide-co-glycolide) nanoparticles. Colloids Surf. A: Physicochem. Eng. Aspects 2006, 276:162-167.
42. Vinogradov S.V., Bronich T.K., Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 2002, 54:135-147.
43. Lin W.J., Lee H.G. Design of a microporous controlled delivery system for theophylline tablets. J. Control. Release 2003, 89:179.
44. Li S.H., Woo E.M. Immiscibility with upper-critical-solution-temperature phase diagrams for poly(methyl methacrylate)/polyesters blends. Colloid Polym. Sci. 2008, 286:253.
45. Elzein T., Nasser-Eddine M., Delaite C., Bistac S., Dumas P. FTIR study of polycaprolactone chain organization at interface. J. Colloid Interface Sci. 2004, 273:381-387.
46. Pamula E., Blazewicza M.C., Paluszkiewiczb Z., Dobrzynski P. FTIR study of degradation products of aliphatic polyesters-carbon fibres composites. J. Mol. Struct. 2001, 596:69-75.
47. Mu L., Seow P.H., Ang S.N., Feng S.S. Study on surfactant coating of polymeric nanoparticles for controlled delivery of anticancer drug. Colloid Polym. Sci. 2004, 283:58-65.
48. Liu K., Kiran E. High-pressure solution blending of polycaprolactone with poly(methyl methacrylate) in acetone plus carbon dioxide. Polymer 2008, 49:1555-1561.
49. Messing R.O., Henteleff M., Park J.J. Ethanol enhances growth factor-induced neurite formation in PC12 cells. Brain Res. 1991, 565:301-311.
50. Traina G., Bagnoli P. Mechanisms mediating somatostatin-induced reduction of cytosolic free calcium in PC12 cells. Neurosci. Let. 1999, 265:123-126.
51. Lambeng N., Michel P.P., Brugg B., Agid Y., Ruberg M. Mechanisms of apoptosis in PC12 cells irreversibly differentiated with nerve growth factor and cyclic AMP. Brain Res. 1999, 821:60-68.
52. Feng S.S., Huang G.F. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Release 2001, 71:53-69.
53. Sokol R.J., Butler-Simon N., Conner C., Heubi J.E., Sinatra F.R., Suchy F.J., Heyman M.B., Perrault J., Rothbaum R.J., Levy J., Iannaccone S.T., Shneider B.L., Koch T.K., Narkewicz M.R. Multicenter trial of d-α-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology 1993, 104:1727-1735.
54. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 1999, 16:1550-1556.
55. Khoo S.M., Porter C.J.H., Charman W.N. The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int. J. Pharm. 2000, 205:65-78.
56. Repka M.A., McGinity J.W. Influence of vitamin E TPGS on the properties of hydrophilic films produced by hot-melt extrusion. Int. J. Pharm. 2000, 202:63-70.